In 2020, LEO Pharma completed a multi-center, randomized Phase 2b dose-finding clinical trial with twice-daily topical delgocitinib cream for the treatment of adults with mild-to-severe CHE.

The primary endpoint for the randomized, double-blind, vehicle-controlled, multi-center Phase 2b dose-finding trial was the proportion of adult patients with mild-to-severe CHE who achieved an ...

BALLERUP, Denmark, July 26, 2024--LEO Pharma Receives Positive CHMP Opinion of Anzupgo® (delgocitinib cream) for the Treatment of Adults with Moderate to Severe Chronic Hand Eczema ...

BALLERUP, Denmark, February 04, 2025--LEO Pharma Achieves Positive DELTA TEEN Trial Results with Anzupgo® (delgocitinib) Cream in Adolescents with Moderate to Severe Chronic Hand Eczema ...

BALLERUP, Denmark, October 30, 2023 -- LEO Pharma A/S, a global leader in medical dermatology, today announced the positive outcome of the DELTA 3 trial.DELTA 3 is a phase 3, single-arm, open-label ...

LEO Pharma, Allergy UK and the CHE Taskforce have published the results of a survey that revealed the real-life impacts and heavy burdens of chronic hand eczema (CHE) that patients experience. The ...

LEO Pharma Receives Positive CHMP Opinion of Anzupgo ® (delgocitinib cream) for the Treatment of Adults with Moderate to Severe Chronic Hand Eczema (CHE) . The positive opinion marks the latest step ...